Saturday 17 October 2026
Export ANTX’s income statement to Excel — free account
AN2 Therapeutics, Inc.
ANTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 14.3% and free cash flow grew 7.91%, each against the same quarter a year earlier. Dividend growth for three consecutive years; insiders bought in the last twelve months.
3.38
0.22
−6.11%
Follow ANTX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
14.32 | 15.73 | 6.87 | 9.33 |
+8 more quarters Free account |
Net Debt/EBITDA |
8.71 | 8.02 | 6.15 | 6.04 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.86 | 1.20 | 0.60 | 0.68 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.16) | (0.35) | (0.17) | (0.21) | |
Cash per Share |
1.75 | 2.50 | 1.92 | 2.05 | |
Shareholders Equity per Share |
1.70 | 2.40 | 1.76 | 1.99 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.70 | 2.40 | 1.76 | 1.99 | |
Free Cash Flow |
(7.00) | (12.07) | (5.24) | (6.37) | |
Working Capital |
74.41 | 81.93 | 51.22 | 57.16 | |
Net Current Asset Value |
74.24 | 81.76 | 51.05 | 57.16 | |
| Other line items | |||||
Quick Ratio |
14.04 | 15.33 | 6.65 | 9.03 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.16) | (0.35) | (0.17) | (0.21) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
2.04 | 2.84 | 3.17 | 1.97 | |
Average Assets |
78.75 | 84.42 | 77.02 | 82.46 | |
Average Common Equity |
72.38 | 77.54 | 67.45 | 74.02 |
Columns are period end dates